# Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

> **NCT02538341** · PHASE2 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 617 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Inflammatory Arthritis
- Arthritis
- Psoriatic Arthritis
- Psoriasis
- Ankylosing Spondylitis
- Enteropathic Arthritis
- Crohn's Disease

## Interventions

- **BIOLOGICAL:** Herpes Zoster (HZ) Vaccine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02538341
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2019-12
- **Final completion:** 2020-12
- **Target enrollment:** 617 (ACTUAL)
- **Last updated:** 2021-11-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02538341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02538341, "Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02538341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*